Plasminogen Activator Inhibitor-1 4G/5G Promoter Polymorphism in Indian Patients with Deep Vein Thrombosis
- PMID: 38708166
- PMCID: PMC11065813
- DOI: 10.1007/s12288-023-01660-3
Plasminogen Activator Inhibitor-1 4G/5G Promoter Polymorphism in Indian Patients with Deep Vein Thrombosis
Abstract
A single guanosine deletion/insertion (4G/5G) polymorphism in the promoter region of plasminogen activator inhibitor-1 (PAI-1) gene encoding PAI-1 protein has been investigated in deep vein thrombosis (DVT) patients. The association between PAI-1 4G/5G polymorphism and increased risk of DVT has been reported in some studies, while others have reported a lack of association. The present study aimed to investigate if the PAI-1 4G/5G polymorphism is associated with an increased risk of DVT in the Indian population and to assess its association with thrombophilic risk factors. Fifty-two adult patients with a history of chronic or recurrent DVT and 52 healthy adult controls were genotyped for PAI-1 4G/5G polymorphism. Plasma levels of PAI-1 and other thrombophilic risk factors were also measured. PAI-1 4G/5G polymorphism was not significantly associated with an increased risk of DVT. Protein C deficiency was significantly associated with the 4G/4G genotype. Patients with the 4G/4G genotype had significantly reduced PAI-1 levels as compared to the controls. PAI-1 4G/5G polymorphism did not significantly contribute to an increased risk of DVT in the Indian population. However, in the presence of thrombophilic risk factor abnormalities, the risk of DVT is increased in individuals with the 4G/4G genotype in the Indian cohort.
Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01660-3.
Keywords: Deep vein thrombosis; Fibrinolysis; PAI-1 4G/5G polymorphism; Plasminogen activator inhibitor-1; Thrombophilia.
© The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2023.
Conflict of interest statement
Conflict of interestThe authors declare that they have no conflict of interest.
Figures

Similar articles
-
PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.Br J Haematol. 2000 Oct;111(1):122-8. doi: 10.1046/j.1365-2141.2000.02321.x. Br J Haematol. 2000. PMID: 11091191
-
Plasminogen Activator Inhibitor-1 4G/5G Promoter Polymorphism in Adults with Splanchnic Vein Thrombosis: A Case-Control Study.Indian J Hematol Blood Transfus. 2022 Jan;38(1):169-172. doi: 10.1007/s12288-021-01454-5. Epub 2021 Jun 18. Indian J Hematol Blood Transfus. 2022. PMID: 35125725 Free PMC article.
-
4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.Thromb Haemost. 1998 Dec;80(6):956-60. Thromb Haemost. 1998. PMID: 9869167
-
Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation.Clin Exp Allergy. 2009 Aug;39(8):1136-44. doi: 10.1111/j.1365-2222.2009.03272.x. Epub 2009 May 5. Clin Exp Allergy. 2009. PMID: 19438580 Review.
-
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.Vasa. 2020 Mar;49(2):141-146. doi: 10.1024/0301-1526/a000839. Epub 2020 Jan 10. Vasa. 2020. PMID: 31920171
References
-
- Seguí R, Estellés A, Mira Y, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000;111:122–128. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous